92 related articles for article (PubMed ID: 15019216)
1. Treatment efficacy of the lead RNAIII-inhibiting peptide YSPWTNF-NH2 in acquired Staphylococcus aureus sepsis: a histopathological assessment.
Ribeiro PD; Ribeiro OD; Marcolan AM; Medina-Acosta E
Peptides; 2003 Nov; 24(11):1829-36. PubMed ID: 15019216
[TBL] [Abstract][Full Text] [Related]
2. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis.
Giacometti A; Cirioni O; Ghiselli R; Dell'Acqua G; Orlando F; D'Amato G; Mocchegiani F; Silvestri C; Del Prete MS; Rocchi M; Balaban N; Saba V; Scalise G
Peptides; 2005 Feb; 26(2):169-75. PubMed ID: 15629527
[TBL] [Abstract][Full Text] [Related]
3. RNAIII-inhibiting peptide in combination with the cathelicidin BMAP-28 reduces lethality in mouse models of staphylococcal sepsis.
Ghiselli R; Giacometti A; Cirioni O; Dell'Acqua G; Bergnach C; Orlando F; Mocchegiani F; Silvestri C; Skerlavaj B; Licci A; Balaban N; Zanetti M; Scalise G; Saba V
Shock; 2006 Sep; 26(3):296-301. PubMed ID: 16912656
[TBL] [Abstract][Full Text] [Related]
4. RIP-V improves murine survival in a sepsis model by down-regulating RNAIII expression and α-hemolysin release of methicillin-resistant Staphylococcus aureus.
Ma B; Zhou Y; Li M; Yu Q; Xue X; Li Z; Da F; Hou Z; Luo X
Pharmazie; 2015 Feb; 70(2):81-7. PubMed ID: 25997246
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat Pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides.
Cirioni O; Giacometti A; Ghiselli R; Dell'Acqua G; Gov Y; Kamysz W; Lukasiak J; Mocchegiani F; Orlando F; D'Amato G; Balaban N; Saba V; Scalise G
Circulation; 2003 Aug; 108(6):767-71. PubMed ID: 12885754
[TBL] [Abstract][Full Text] [Related]
6. Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.
Dell'Acqua G; Giacometti A; Cirioni O; Ghiselli R; Saba V; Scalise G; Gov Y; Balaban N
J Infect Dis; 2004 Jul; 190(2):318-20. PubMed ID: 15216467
[TBL] [Abstract][Full Text] [Related]
7. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis.
Gov Y; Bitler A; Dell'Acqua G; Torres JV; Balaban N
Peptides; 2001 Oct; 22(10):1609-20. PubMed ID: 11587789
[TBL] [Abstract][Full Text] [Related]
8. RNAIII-inhibiting peptide and/or nisin inhibit experimental vascular graft infection with methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis.
Ghiselli R; Giacometti A; Cirioni O; Dell'Acqua G; Mocchegiani F; Orlando F; D'Amato G; Rocchi M; Scalise G; Saba V
Eur J Vasc Endovasc Surg; 2004 Jun; 27(6):603-7. PubMed ID: 15121110
[TBL] [Abstract][Full Text] [Related]
9. RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections.
Cirioni O; Giacometti A; Ghiselli R; Dell'Acqua G; Orlando F; Mocchegiani F; Silvestri C; Licci A; Saba V; Scalise G; Balaban N
J Infect Dis; 2006 Jan; 193(2):180-6. PubMed ID: 16362881
[TBL] [Abstract][Full Text] [Related]
10. Prevention of lethal murine candidiasis using HP (2-20), an antimicrobial peptide derived from the N-terminus of Helicobacter pylori ribosomal protein L1.
Ribeiro PD; Medina-Acosta E
Peptides; 2003 Nov; 24(11):1807-14. PubMed ID: 15019213
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Staphylococcus aureus pathogenesis in vitro and in vivo by RAP-binding peptides.
Yang G; Cheng H; Liu C; Xue Y; Gao Y; Liu N; Gao B; Wang D; Li S; Shen B; Shao N
Peptides; 2003 Nov; 24(11):1823-8. PubMed ID: 15019215
[TBL] [Abstract][Full Text] [Related]
12. RNAIII-inhibiting-peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation.
Anguita-Alonso P; Giacometti A; Cirioni O; Ghiselli R; Orlando F; Saba V; Scalise G; Sevo M; Tuzova M; Patel R; Balaban N
Antimicrob Agents Chemother; 2007 Jul; 51(7):2594-6. PubMed ID: 17116671
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis.
Cirioni O; Ghiselli R; Orlando F; Silvestri C; De Luca S; Salzano AM; Mocchegiani F; Saba V; Scalise G; Scaloni A; Giacometti A
Crit Care Med; 2008 Sep; 36(9):2629-33. PubMed ID: 18679116
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
Balaban N; Cirioni O; Giacometti A; Ghiselli R; Braunstein JB; Silvestri C; Mocchegiani F; Saba V; Scalise G
Antimicrob Agents Chemother; 2007 Jun; 51(6):2226-9. PubMed ID: 17371825
[TBL] [Abstract][Full Text] [Related]
15. RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus.
Simonetti O; Cirioni O; Ghiselli R; Goteri G; Scalise A; Orlando F; Silvestri C; Riva A; Saba V; Madanahally KD; Offidani A; Balaban N; Scalise G; Giacometti A
Antimicrob Agents Chemother; 2008 Jun; 52(6):2205-11. PubMed ID: 18391046
[TBL] [Abstract][Full Text] [Related]
16. BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci.
Domenico P; Gurzenda E; Giacometti A; Cirioni O; Ghiselli R; Orlando F; Korem M; Saba V; Scalise G; Balaban N
Peptides; 2004 Dec; 25(12):2047-53. PubMed ID: 15572191
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.
Hegde SS; Reyes N; Skinner R; Difuntorum S
J Antimicrob Chemother; 2008 Jan; 61(1):169-72. PubMed ID: 17993505
[TBL] [Abstract][Full Text] [Related]
18. RNAIII Inhibiting Peptide (RIP) and Derivatives as Potential Tools for the Treatment of S. aureus Biofilm Infections.
Ciulla M; Di Stefano A; Marinelli L; Cacciatore I; Di Biase G
Curr Top Med Chem; 2018; 18(24):2068-2079. PubMed ID: 30345922
[TBL] [Abstract][Full Text] [Related]
19. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus.
Balaban N; Goldkorn T; Nhan RT; Dang LB; Scott S; Ridgley RM; Rasooly A; Wright SC; Larrick JW; Rasooly R; Carlson JR
Science; 1998 Apr; 280(5362):438-40. PubMed ID: 9545222
[TBL] [Abstract][Full Text] [Related]
20. Effects of toxin production in a murine model of Staphylococcus aureus keratitis.
Girgis DO; Sloop GD; Reed JM; O'Callaghan RJ
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2064-70. PubMed ID: 15914624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
